Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05070767
Other study ID # NLR - 210720
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 18, 2021
Est. completion date May 30, 2022

Study information

Verified date October 2023
Source Neurolens Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To understand the benefits of the neurolens Measurement Device and neurolens treatment as it pertains to treating symptoms related to Chronic Headaches. It is a Prospective randomized double masked two arm performed on a minimum of 200 to a maximum of 300 subjects identified as symptomatic (HIT-6 questionnaire score equal to or greater than 56) done across 3-15 clinical sites. There are two subgroups: a minimum of 100 in each subgroup (subgroup 1: pre-presbyopic (18-40 years); subgroup 2: presbyopic subjects (41-60 years).


Description:

This study is a two-arm crossover study with two subgroups. Subjects will initially be assessed for their headache symptoms (Headache Impact Test (HIT-6) questionnaire) and then are provided an updated refractive prescription and will wear them for 35 ± 5 days. Symptoms will be reassessed after the 35-day control break in. If the subject's symptoms have subsided, they will be exited from the study and will keep their lenses. Provided the subject has symptoms (HIT questionnaire score ≥ 56) after their 35-day use of their updated prescription and they continue to meet the inclusion/exclusion criteria they will proceed to the evaluation portion of the protocol. The first arm receiving neurolens first and the second arm receiving the control first. The control is a single vision or PAL lens which yields the BCDVA and BCNVA of a test subject with no prismatic correction. The neurolens prescribed prism will be based on the practitioner's Rx using the subject's best response to a prism trial lens and must be within a half prism diopter of the neurolens value output of the neurolens Measurement Device and providing the subject's BCDVA and BCNVA. Participants will come back after 35 day wear of their first test lens and the symptom questionnaire is reassessed. They will be now be crossed over to the second pair of study lenses (i.e. subjects in the first arm will not receive control lens and the ones in the second arm will not receive neurolens). Participants will come back after 35 day wear of their second test lens and the symptom questionnaire is reassessed for the final time.


Recruitment information / eligibility

Status Completed
Enrollment 300
Est. completion date May 30, 2022
Est. primary completion date May 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Male or female, and between 18-60 years of age at the time of signing the informed consent. - Best Corrected distance and near acuity are equal to or better than 20/25 Snellen Equivalent in each eye. - Best Corrected distance and near binocular acuity are equal to or better than 20/25 Snellen Equivalent. - Symptomatic as indicated by the HIT-6 questionnaire (Score equal to or greater than 56) - Updated distance spectacle prescription must match the following a. Spherical power inclusive between +4.00D to -8.00D b. Cylinder power no more than -4.00Dcyl c. ADD power i. Subgroup 1: No ADD ii. Subgroup 2: minimum +1.00D ADD - Subjects' eye alignment tests must match the following: a. Successful measurement on the neurolens Measurement Device (Acceptable MQI and a numerical neurolens Value, no Low MQI or Convergence Excess) - Minimum stereo vision of 50 seconds of arc at 16 inches - Capable of committing to the duration of the study. - Willing to comply with study procedures Exclusion Criteria: - Subjects who need a vertical prism. - Previously has worn neurolenses. - Subjects who need a near add less than 1.00D - Use of contact lenses during the study - Lack of binocular vision, including strabismus, amblyopia, or suppression. - Greater than 20 prism diopter of eye misalignment. - Aniseikonia greater than 3.00D spherical equivalent difference between eyes - Prior ocular surgery that in the estimation of the practitioner induces corneal scarring (RK, Corneal Transplant, etc.) or prior surgery involving the extraocular muscles (strabismus surgery). Surgeries that do not affect these parameters such as LASIK, PRK, or pterygium surgery are allowed. - Anterior segment conditions that could obfuscate or obscure reflections from the cornea, or reduce visual acuity, including but not limited to corneal scarring, large pinguecula, pterygium, keratoconus, dermatochalasis, ptosis, exophthalmos or cataract. - Clinical dry eye (defined as tear break-up time of less than 5 seconds) - Intraocular pressures greater than 25 mmHg in either eye or uncontrolled glaucoma - Macular disease, or any posterior segment finding which in the opinion of the investigator is visually and/or clinically significant - Change in acute or prophylactic migraine treatment medication or dosage within the previous two months. - Diabetes with ocular manifestation - Previous head or neck trauma (for instance, car accident, etc.) requiring medical intervention. - Open lesions or sores around the chin or eyes that will make contact with the device and may be subject to contraction or spread of infection. - Physical tremors or muscle spasms that prevent a subject from sitting still. - A history of seizures or seizure disorder. - Women who are pregnant or lactating at the time of the study entry - Mental incapacity that prevents a subject from being able to follow simple instructions such as "look at the target."

Study Design


Intervention

Device:
Neurolens spectacle lens
spectacle lens
Placebo spectacle lens
spectacle lens for refractive error correction

Locations

Country Name City State
United States Kapperman White and McGarvey Chattanooga Tennessee
United States The Eye Center Conyers Georgia
United States Buckeye Family Eye Clinic Hillsboro Ohio
United States Signature Eye Care Lincoln Nebraska
United States Preferred Eye Care Center Mount Pleasant South Carolina
United States Advanced Eyecare Center Perry Georgia
United States Advanced Vision and Achievement Center Phoenix Arizona
United States Eyecare of Rigby Rigby Idaho
United States Eyes for Life Spokane Washington
United States Springhill Eye Care Spring Hill Tennessee

Sponsors (1)

Lead Sponsor Collaborator
Neurolens Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Headache Impact Test (HIT-6) questionnaire Change in headache impact test (HIT-6) with the use of neurolenses compared to control lenses.
The minimum response score for each question is 6 and the maximum is 13. Larger scores would indicate a more symptomatic patient.
Larger difference in the cumulative response score between treatment visit and the baseline visit would indicate a greater impact of the treatment.
30-40 days
Secondary Patients with reduced near point of convergence (NPC) Change in the headache impact test (HIT-6) score with the use of neurolens compared to control lenses in subjects with reduced Near point of convergence (NPC).
The minimum response score for each question is 6 and the maximum is 13. Larger scores would indicate a more symptomatic patient.
Larger difference in the cumulative response score between treatment visit and the baseline visit would indicate a greater impact of the treatment.
30-40 days
See also
  Status Clinical Trial Phase
Withdrawn NCT03472872 - A Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache Phase 4
Withdrawn NCT05410366 - Safe Harbors in Emergency Medicine, Specific Aim 3
Withdrawn NCT02866084 - Neuromodulation Treatment of Vestibular Migraines N/A
Active, not recruiting NCT03537573 - Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care N/A
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Not yet recruiting NCT04352218 - Safety Profile of PETALO CVS in the Treatment of Non-thrombotic Internal Jugular Vein Stenosis and Chronic Headache Phase 2
Completed NCT02734992 - Acceptance and Commitment Therapy vs Medical Treatment as Usual Wait-list Control for Primary Headache Sufferers N/A
Completed NCT01153789 - Study of Oculomotor Dysfunction Leading to Children Vertigo N/A
Completed NCT01327118 - Prostaglandin F2alpha in a Human Headache Model N/A
Not yet recruiting NCT00969995 - Identification of Inflammatory Markers in Migraine Patients N/A
Not yet recruiting NCT00752921 - Randomized Placebo Controlled Trial With Etoricoxib That is Taken to Prevent the Yom Kippur Headache Phase 4
Completed NCT00212810 - Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache. Phase 4
Terminated NCT00291395 - PGI2 Induced Headache and Cerebral Haemodynamics in Healthy Volunteers Phase 1
Completed NCT00263094 - An End to the Yom Kippur (and Ramadan) Headache N/A
Completed NCT00135122 - Prednisolone in the Treatment of Withdrawal Headache in Probable Medication Overuse Headache Phase 3
Completed NCT02475005 - An Intervention to Improve Adolescent Headache Self-management N/A
Completed NCT03163901 - The Effect of OMT on Functional Outcomes and Anti-inflammatory Biomarkers in Mild to Moderate Traumatic Brain Injury N/A
Completed NCT01664585 - Exercise Training With Physically Active Lifestyle to Reduce Headache and Quality of Life N/A
Completed NCT04632420 - Evaluation of Headache and Childbirth in a Chronic Pain Population
Recruiting NCT05033613 - Home Blood Pressure Monitoring Before and After COVID-19 Vaccination in Patients at High Risk of Cardiovascular Disease